Anavex Life Sciences Corp (AVXL)

[La Flaca]

The most recently approved drug for ALZ, Lecanemab, was approved based on meeting the CDR-SB primary endpoint and plasma and amyloid-beta biomarkers. Blarcamesine's clinical trial measured ADAS Cog and ADCS-ADL as primary endpoints and CDR-SB as secondary, plus brain atrophy, Tau, and amyloid-beta. All stat. significant, but the ADCS-ADL achieved it outside of the 48 week period. Nonetheless, there's never been a better performing drug that has filed for approval with EMA.